Cargando…

Efficacy of anti–tumor necrosis factor therapy for extra-articular manifestations in patients with ankylosing spondylitis: a meta–analysis

BACKGROUND: We performed a meta-analysis to evaluate the effect of anti–tumor necrosis factor (TNF) therapy on the frequency of extra–articular manifestations (EAMs) in patients with ankylosing spondylitis (AS). METHODS: We searched with the terms ‘ankylosing spondylitis’, ‘infliximab’, ‘etanercept’...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Dan, Guo, Ying-Ying, Xu, Nan-Nan, Zhao, Shuai, Hou, Lin-Xin, Jiao, Ting, Zhang, Ning
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4328050/ https://www.ncbi.nlm.nih.gov/pubmed/25888248 http://dx.doi.org/10.1186/s12891-015-0489-2

Ejemplares similares

Extra-Articular Manifestations in Patients with Ankylosing Spondylitis: Baseline Characteristics from the RBSMR Study
por: Ouardi, Najlae El, et al.
Publicado: (2022)

Cardiopulmonary Manifestations of Ankylosing Spondylitis
por: Momeni, Mahnaz, et al.
Publicado: (2011)

Incidence of extra-articular manifestations in ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis: results from a national register-based cohort study
por: Bengtsson, Karin, et al.
Publicado: (2020)

Impact of extra-articular spondyloarthritis manifestations and comorbidities on drug retention of a first TNF-inhibitor in ankylosing spondylitis: a population-based nationwide study
por: Lindström, Ulf, et al.
Publicado: (2018)

Is Nephrolithiasis an Unrecognized Extra-Articular Manifestation in Ankylosing Spondylitis? A Prospective Population-Based Swedish National Cohort Study with Matched General Population Comparator Subjects
por: Jakobsen, Ane Krag, et al.
Publicado: (2014)

Predictors of extra-articular manifestations in axial spondyloarthritis and their influence on TNF-inhibitor prescribing patterns: results from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis
por: Derakhshan, Mohammad H, et al.
Publicado: (2020)

Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis
por: de Winter, Janneke J., et al.
Publicado: (2016)

Predictors of Switching Anti-Tumor Necrosis Factor Therapy in Patients with Ankylosing Spondylitis
por: Lee, Jeong-Won, et al.
Publicado: (2015)

Adverse Events of Anti-Tumor Necrosis Factor α Therapy in Ankylosing Spondylitis
por: Tong, Qiang, et al.
Publicado: (2015)

Correction: Adverse Events of Anti-Tumor Necrosis Factor α Therapy in Ankylosing Spondylitis
por: Tong, Qiang, et al.
Publicado: (2015)

Peptidomics analysis of plasma in patients with ankylosing spondylitis
por: Zhang, Guo-ning, et al.
Publicado: (2023)

Efficacy and safety of adalimumab in ankylosing spondylitis
por: Mounach, Aziza, et al.
Publicado: (2014)

Palmoplantar pustulosis secondary to anti-tumor necrosis factor therapy in a patient with ankylosing spondylitis
por: Bae, Jung Min, et al.
Publicado: (2020)

Ankylosing spondylitis
Publicado: (1980)

Ankylosing spondylitis
por: Edavalath, Mukesh
Publicado: (2010)

Ankylosing Spondylitis
por: Whitfield, A. G. W.
Publicado: (1976)

Ankylosing Spondylitis
por: Ebrahimiadib, Nazanin, et al.
Publicado: (2021)

Anti-TNF-α Therapy for Ankylosing Spondylitis
por: Son, Jung-Hwan, et al.
Publicado: (2010)

Anti-tumor necrosis factor treatment in ankylosing spondylitis may not relate to poor prognosis in COVID-19
por: ŞEN, Nesrin, et al.
Publicado: (2020)

The impact of smoking status on radiographic progression in patients with ankylosing spondylitis on anti-tumor necrosis factor treatment
por: Nam, Bora, et al.
Publicado: (2022)

Andersson Lesion in Ankylosing Spondylitis
por: Wu, Xin, et al.
Publicado: (2022)

Effect of Tumor Necrosis Factor Inhibitor Therapy on Osteoclasts Precursors in Ankylosing Spondylitis
por: Perpétuo, Inês P., et al.
Publicado: (2015)

The Effect of Tumor Necrosis Factor-Alpha Inhibitors on Uveitis in Patients with Ankylosing Spondylitis
por: Lee, Suhwan, et al.
Publicado: (2019)

Synchronous or sequential cementless bilateral total hip arthroplasty for osseous ankylosed hips with ankylosing spondylitis
por: Mou, Ping, et al.
Publicado: (2021)

Imaging of ankylosing spondylitis
por: Østergaard, Mikkel
Publicado: (2012)

Alexithymia in ankylosing spondylitis
por: Karabıçak, Deniz, et al.
Publicado: (2021)

Identification of lncRNAs associated with the pathogenesis of ankylosing spondylitis
por: Huang, Dan, et al.
Publicado: (2021)

Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy
por: Rudwaleit, Martin, et al.
Publicado: (2010)

Autoimmune Encephalitis as an Extra-articular Manifestation of Rheumatoid Arthritis
por: Kitamura, Eiji, et al.
Publicado: (2018)

Influence factors of extra-articular manifestations in rheumatoid arthritis
por: Chen, Xing, et al.
Publicado: (2020)

Post-transplant manifestation of ankylosing spondylitis: a case report and review of literature
por: Anna, Zawiasa-Bryszewska, et al.
Publicado: (2021)

Case Report: A Rare Manifestation of Pulmonary Arterial Hypertension in Ankylosing Spondylitis
por: Yang, Tsung-Yuan, et al.
Publicado: (2022)

Impact of Dose Tapering of Tumor Necrosis Factor Inhibitor on Radiographic Progression in Ankylosing Spondylitis
por: Park, Jun Won, et al.
Publicado: (2016)

Drug survival of tumor necrosis factor α inhibitors in patients with ankylosing spondylitis in Korea
por: Jeong, Hyemin, et al.
Publicado: (2018)

Predicting Probability of Response to Tumor Necrosis Factor Inhibitors for Individual Patients With Ankylosing Spondylitis
por: Wang, Runsheng, et al.
Publicado: (2022)

Osteogenic differentiation characteristics of hip joint capsule fibroblasts obtained from patients with ankylosing spondylitis
por: Jiang, Nan, et al.
Publicado: (2021)

Predominant frequency of HLA‐B*27 in patients with ankylosing spondylitis in southeastern China
por: Lu, JiaoJiao, et al.
Publicado: (2021)

Clinical response to the anti-tumor necrosis factor alpha antibody infliximab in patients with ankylosing spondylitis over 3 years
por: Baraliakos, X, et al.
Publicado: (2005)

Tumor Necrosis Factor-Alpha (+489 G/A) Polymorphism Can Predict the Response to Adalimumab in Chinese Han Patients With Ankylosing Spondylitis
por: Liang, Hong-Jin, et al.
Publicado: (2023)

Reactive Arthritis Triggered by Adalimumab and Leflunomide in a Patient with Ankylosing Spondylitis
por: Liu, Ying, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gsst4k2lluueds1gp6slpmpgog